Amylase and lipase =< 1.5 x ULN without any symptoms of pancreatitisXx_NEWLINE_xXPARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN, within 2 weeks prior to enrollmentXx_NEWLINE_xXPARTICIPANTS ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Serum lipase and amylase < 1.5 x ULN, within 2 weeks prior to enrollmentXx_NEWLINE_xXSerum lipase =< ULN at baseline; patients with glucose intolerance should be on a stable regimen and be monitoredXx_NEWLINE_xXSerum amylase =< 1.5 x ULNXx_NEWLINE_xXSerum lipase =< 1.5 x ULNXx_NEWLINE_xXPatients must have amylase or lipase within =< 1.5 x IULN without symptoms of pancreatitis at registration, within 28 days prior to registrationXx_NEWLINE_xXSerum amylase =< 1.5 ULNXx_NEWLINE_xXSerum lipase =< 1.5 ULNXx_NEWLINE_xXLipase: 1.5 x ULN. Subjects with lipase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitisXx_NEWLINE_xXAmylase: 1.5 x ULN. Subjects with amylase >1.5 x ULN may enrol if there are neither clinical or radiographic signs of pancreatitisXx_NEWLINE_xXSerum pancreatic amylase < 1.5 x ULNXx_NEWLINE_xXSerum pancreatic lipase < 1.5 x ULNXx_NEWLINE_xXSerum lipase =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXLipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis, within 14 days before the first dose of cabozantinibXx_NEWLINE_xXSerum lipase and amylase =< 1.5 x ULNXx_NEWLINE_xXLipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis within 7 days before the first dose of cabozantinibXx_NEWLINE_xXAmylase/lipase =< 1.5 x institutional ULN (without symptoms of pancreatitis)Xx_NEWLINE_xXLipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXEXCLUSION - INFUSION: Lipase > 70 U/mlXx_NEWLINE_xXAsymptomatic serum amylase =< grade 2 and asymptomatic serum lipase =< grade 2; patients with grade 1 or grade 2 serum amylase or lipase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.), at the screening visitXx_NEWLINE_xXAsymptomatic serum amylase =< 2 x ULN; patients with > ULN but =< 2 x ULN serum amylase at study start must be confirmed to have no signs and/or symptoms suggestion pancreatitis or pancreatic injury (e.g. elevated pancreatic [P]-amylase, abnormal imaging findings of pancreas, etc.)Xx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXHistory of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.Xx_NEWLINE_xXAmylase =< 1 x ULN.Xx_NEWLINE_xXLipase =< 1 x ULN.Xx_NEWLINE_xXAmylase and lipase =< 2 x ULNXx_NEWLINE_xXSerum amylase =< 1.5 X institutional ULNXx_NEWLINE_xXLipase =< 1.5 X institutional ULNXx_NEWLINE_xXObtained within 28 days prior to the first dose of cabozantinib: lipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis.Xx_NEWLINE_xXAmylase and lipase < 1.5 x ULN obtained ? 14 days prior to randomizationXx_NEWLINE_xXLipase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXAmylase and lipase =< 1.5 ULN; subjects with amylase or lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of pancreatitisXx_NEWLINE_xXSerum lipase and amylase =< 1.5 x ULN.Xx_NEWLINE_xXSerum lipase > 1.5 x ULNXx_NEWLINE_xXSerum lipase and amylase =< 1.5 x ULN.Xx_NEWLINE_xXLipase =< 1.5 x ULNXx_NEWLINE_xXSerum amylase/lipase =< 1.5 x ULNXx_NEWLINE_xXSerum amylase =< 2 x ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXPatient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic diseaseXx_NEWLINE_xXLipase =< 3 x ULNXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXLipase =< ULNXx_NEWLINE_xXFULL STUDY INCLUSION CRITERIA: Amylase and lipase =< 1.5 x ULNXx_NEWLINE_xXLipase < 2 ULNXx_NEWLINE_xXNote: in the absence of clinical symptoms of pancreatitis, elevations of amylase or lipase are not contraindications to therapy on this trialXx_NEWLINE_xXSerum amylase and lipase =< 2 x ULNXx_NEWLINE_xXSerum amylase and lipase =< 1.5 x ULNXx_NEWLINE_xXSerum amylase and lipase =< 1.5 x institutional ULNXx_NEWLINE_xXNormal serum lipase and amylase (per institutional normal values)Xx_NEWLINE_xXSerum amylase =< 2 x ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXHistory of pancreatitis or history of increased amylase or lipase that was due to pancreatitisXx_NEWLINE_xXLipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Serum amylase =< grade 2 and asymptomatic; patients with grade 1 or 2 serum amylase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)Xx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Serum lipase =< ULNXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Serum lipase =< ULNXx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: History of pancreatitis, or history of increased amylase or lipase that was due to pancreatic diseaseXx_NEWLINE_xXSerum amylase =< 2 x ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXPatient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic diseaseXx_NEWLINE_xXLipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXHave normal pancreatic status as defined by the following criterion: a. Serum lipase and amylase ? 1.5 × ULNXx_NEWLINE_xXAmylase =< 2 X ULNXx_NEWLINE_xXFor patients being screened for Group 2, asymptomatic serum amylase > CTCAE Grade 2 (1.5-2.0 x ULN). Patients with Grade 1 or Grade 2 serum amylase at the beginning of the study must be confirmed to have no signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)Xx_NEWLINE_xXFor patients being screened for Group 2: Serum lipase > ULNXx_NEWLINE_xXLipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.Xx_NEWLINE_xXWithin 4 days prior to the first dose of cabozantinib: Lipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXSerum amylase =< 2 x ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXPatient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic diseaseXx_NEWLINE_xXSerum lipase and amylase =< 1.5 x ULNXx_NEWLINE_xXSerum lipase =< 2 x ULNXx_NEWLINE_xXSerum amylase =< 2 x ULNXx_NEWLINE_xXLipase < 2.0 x ULN; no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXLipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXSerum lipase and amylase =< 1.5 x ULNXx_NEWLINE_xXSerum lipase =< 1.5 x institutional upper limit of normalXx_NEWLINE_xXAsymptomatic serum amylase grade > 2 (1.5-2.0 x ULN). Patients with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)Xx_NEWLINE_xXSerum lipase > ULNXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXWithin 14 days prior to first dose of study drug treatment: Amylase and lipase =< 1.5 x ULNXx_NEWLINE_xXWithin 7 days before the first dose of cabozantinib: Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXAmylase < ULNXx_NEWLINE_xXLipase < ULNXx_NEWLINE_xXSerum amylase and lipase within normal limitsXx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXAmylase =< 1.5 x the ULNXx_NEWLINE_xXWithin 14 days prior to registration: Serum amylase =< 1.5 x institution’s ULNXx_NEWLINE_xXWithin 14 days prior to registration: Serum lipase =< 1.5 x institution’s ULNXx_NEWLINE_xXAmylase and/or lipase =< 1.5 x ULN, obtained =< 7 days prior to registrationXx_NEWLINE_xXLipase < 2.0 x ULN; no radiologic/clinical evidence of pancreatitisXx_NEWLINE_xXLipase > 1.5 ULN; participants with lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitisXx_NEWLINE_xXAmylase > 1.5 ULN; participants with amylase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitisXx_NEWLINE_xXLipase < 1.5 times the ULNXx_NEWLINE_xXFasting serum amylase =< 2 x institutional ULNXx_NEWLINE_xXFasting serum lipase =< institutional ULNXx_NEWLINE_xXPatients must have a lipase and amylase performed within 7 days prior to sub-study registrationXx_NEWLINE_xXSerum amylase and lipase =< 1.5 x the ULNXx_NEWLINE_xXSerum lipase =< upper limit of normalXx_NEWLINE_xXAmylase =< 1.5 x ULNXx_NEWLINE_xXLipase =< 1.5 x ULNXx_NEWLINE_xXWithin 14 days of subject registration: Serum amylase =< 2 x ULN and serum lipase within normal limitsXx_NEWLINE_xXAmylase or lipase within normal limit (per institutional standards)Xx_NEWLINE_xXLipase =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXAmylase (0-160 U/L) and lipase (0-130 U/L) levels within 1.5 times the range of normalXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXAmylase and lipase =< 1.5 x the upper limit of normalXx_NEWLINE_xXPatients must have a lipase, amylase, TSH with reflex free T3/T4 performed within 7 days prior to sub-study registration; (Note: For the Canadian sites, testing for lipase only is acceptable)Xx_NEWLINE_xXAmylase and lipase <=ULN [Applies to Phase 2].Xx_NEWLINE_xXLipase < 2 X the upper limit of normal (ULN) and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXLipase performed within 28 days of randomization must be less than or equal to 1.5 x ULN for the lab.Xx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXAmylase and lipase ? 2X upper limit of normalXx_NEWLINE_xXLipase ? 1.5 x ULNXx_NEWLINE_xXAsymptomatic serum amylase or lipase > Grade 2Xx_NEWLINE_xXSerum amylase or serum lipase CTCAE grade ? 1 with signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g. elevated P-amylase, abnormal imaging findings of pancreas, etc)Xx_NEWLINE_xXAdequate pancreatic function, defined as amylase and lipase less than or equal to 1.5 X ULNXx_NEWLINE_xXAmylase and lipase =< 2 times institutional ULN for ageXx_NEWLINE_xXObtained =< 7 days prior to registration:\r\nSerum amylase and lipase =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXLipase less than or equal to 2 x ULNXx_NEWLINE_xXPatient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic disease.Xx_NEWLINE_xXSerum lipase and amylase =< 2.5 x ULN; NOTE: if subject has tumor involvement in the liver =< 3 x ULNXx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXAmylase =< 1.5 x the ULNXx_NEWLINE_xXSerum lipase/amylase ?1.5 x ULNXx_NEWLINE_xXSerum lipase =< upper limit of normalXx_NEWLINE_xXLipase =< 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXSerum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN.Xx_NEWLINE_xXAmylase and lipase equal to, or less than, the institutional ULNXx_NEWLINE_xXPART B: Serum lipase =< 1.5 X ULNXx_NEWLINE_xXPART B: Serum amylase =< 1.5 X ULNXx_NEWLINE_xXNormal serum amylase =< (ULN) OR normalXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXObtained =< 7 days prior to registration: Serum lipase =< 1.5 x ULNXx_NEWLINE_xXSerum lipase ? 2 x ULNXx_NEWLINE_xXLipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXLipase < 2 x the upper limit of normalXx_NEWLINE_xXSerum lipase < 3 X institutional upper limit of normalXx_NEWLINE_xXLipase < 1.5 x upper limit of normalXx_NEWLINE_xXSerum amylase =< 1.5 x ULNXx_NEWLINE_xXSerum lipase =< 1.5 x ULNXx_NEWLINE_xXHave Amylase =< 2.5x ULNXx_NEWLINE_xXAmylase and lipase levels =< ULNXx_NEWLINE_xXAmylase and lipase =< 1.5 x ULNXx_NEWLINE_xXAmylase < 1.5 times ULNXx_NEWLINE_xXAmylase and lipase < 1.5 x of ULNXx_NEWLINE_xXSerum amylase or lipase <1.5 x ULN;Xx_NEWLINE_xXAmylase and lipase =< 2 x ULNXx_NEWLINE_xXAmylase and lipase ? 2.5 x ULN (? 5 x ULN for subjects with pancreas involvement with tumor)Xx_NEWLINE_xXLipase levels < 1.5 X ULNXx_NEWLINE_xXAmylase levels < 1.5 X ULNXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXAmylase =< 1.5 x the ULNXx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXSerum lipase ? 3 x ULN and serum amylase within the normal rangeXx_NEWLINE_xXSerum lipase ? 3 x ULN and serum amylase within the normal rangeXx_NEWLINE_xXLipase and amylase =< 1.5 x ULNXx_NEWLINE_xXLipase</=1.5 times the ULNXx_NEWLINE_xXSerum lipase > normal limits for the institutionXx_NEWLINE_xXAsymptomatic serum amylase > grade 2Xx_NEWLINE_xXLipase =< 1.5 x ULNXx_NEWLINE_xXLipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXSerum amylase =< 2 x ULNXx_NEWLINE_xXSerum lipase =< 1 x ULNXx_NEWLINE_xXHistory of pancreatitis or history of increased amylase or lipase that was due to pancreatic diseaseXx_NEWLINE_xXLipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXSerum amylase =< upper limit of normal (ULN) (if > ULN, confirm pancreatic amylase < 1 .1ukat/L and serum lipase < ULN)Xx_NEWLINE_xXLipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xXSerum amylase and lipase within normal limitsXx_NEWLINE_xXAmylase =< 1.5 x ULNXx_NEWLINE_xXLipase =< 1.5 x ULNXx_NEWLINE_xXAmylase and lipase ? 1.5 x ULNXx_NEWLINE_xXHistory of pancreatitis, or amylase > ULNXx_NEWLINE_xXHistory of lipase > ULNXx_NEWLINE_xXLipase < 1.5 x the upper limit of normalXx_NEWLINE_xXSerum amylase =< ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXAmylase and Lipase < 1.5 x normal for age.Xx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXLipase < 2.0 x ULN and no radiologic or clinical evidence of pancreatitisXx_NEWLINE_xX>= grade 2 lipase increased (> 1.5 x ULN)Xx_NEWLINE_xXAny history of an immune-related Grade 4 adverse event attributed to prior CIT (other than endocrinopathy managed with replacement therapy or asymptomatic elevation of serum amylase or lipase)Xx_NEWLINE_xXPatients with a prior or current history of a second malignancy, impaired GI function, history of pancreatitis or increased amylase or lipase, known diagnosis of HIV, and clinically significant cardiac disease were excluded.Xx_NEWLINE_xXLipase =< 2 × upper limits of normalXx_NEWLINE_xXAmylase =< 1.5 x ULNXx_NEWLINE_xXLipase =< 1.5 x ULNXx_NEWLINE_xXSerum amylase =< 2 x ULNXx_NEWLINE_xXSerum lipase =< ULNXx_NEWLINE_xXPatient has a history of pancreatitis or history of increased amylase or lipase that was due to pancreatic diseaseXx_NEWLINE_xXLipase =< 1.5 x the ULNXx_NEWLINE_xXLipase =< 1.5 ULNXx_NEWLINE_xXLipase <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.Xx_NEWLINE_xXLipase ?1.5×ULN and amylase ?1.5×ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis.Xx_NEWLINE_xXAt least two episodes of acute pancreatitis in the past 12 months; acute pancreatitis is defined any 2 of the following: (1) typical upper abdominal pain; (2) elevation in serum amylase or lipase >= 3 times upper limit of normal; (3) features of acute pancreatitis on cross-sectional imagingXx_NEWLINE_xXSerum lipase =< upper limit of normal (IULN)Xx_NEWLINE_xXSerum lipase =< 1.5 x ULNXx_NEWLINE_xXSerum lipase ? 2 x ULN i.e. equivalent to ? Grade 2 NCI-CTCAE v.4.03Xx_NEWLINE_xXLipase must be <=1.5*ULN and amylase <=1.5*ULN with no clinical symptoms suggestive of pancreatitis and cholecystitis.Xx_NEWLINE_xX